Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Fast Route To EU Market For Dova's Avatrombopag

Executive Summary

Dova’s avatrombopag, which was recently approved in the US under priority review, has been refused an accelerated assessment in the EU.

You may also be interested in...



Pfizer’s Talazoparib Among Bumper Crop Of New Products Under Review By EMA

Fourteen new products have been added to the European Medicines Agency’s list of medicines under review for marketing authorization across the EU.

Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya

The European Medicines Agency’s pharmacovigilance committee has recommended more restrictions on the use of Richter’s Esmya because of concerns over the risk of serious liver damage.

Dova Keeps Mum On EU Fast-Track Request Outcome; Requests Well Down

There has been a sharp fall in the number of companies seeking accelerated assessment for their investigational products at the European Medicines Agency. One such company that has asked – Dova Pharmaceuticals – is staying silent on the outcome of its request.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel